Avoro Capital Advisors’s Soleno Therapeutics SLNO Stock Holding History

Avoro Capital Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,300,000	Closed	-$77M	–	32
2026 Q1	$77M	Sell	2,300,000 -600,000	-21%	-$23.5M	0.76%	22
2025 Q4	$134M	Buy	2,900,000 +322,223	+13%	+$17.7M	1.32%	19
2025 Q3	$174M	Buy	2,577,777 +527,777	+26%	+$39.1M	2.25%	16
2025 Q2	$172M	Sell	2,050,000 -475,000	-19%	-$35.6M	3.01%	11
2025 Q1	$180M	Hold	2,525,000	–	–	2.82%	10
2024 Q4	$113M	Buy	2,525,000 +344,000	+16%	+$17.8M	1.61%	16
2024 Q3	$110M	Buy	2,181,000 +89,334	+4%	+$4.28M	1.61%	18
2024 Q2	$85.3M	Buy	2,091,666 +466,666	+29%	+$19.8M	1.14%	21
2024 Q1	$69.5M	Buy	1,625,000 +840,000	+107%	+$38M	0.81%	27
2023 Q4	$31.6M	Buy	+785,000	New	+$22.3M	0.44%	31

Avoro Capital Advisors's SLNO Position: Q2 2026 in Review

Avoro Capital Advisors sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 2,300,000 shares — an estimated $77M sold.

Avoro Capital Advisors first reported a position in SLNO in Q4 2023 and held it in 10 quarters. The position peaked at $180M in Q1 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Avoro Capital Advisors reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Avoro Capital Advisors sold 2,300,000 Soleno Therapeutics shares in Q2 2026, an estimated $77M.
Avoro Capital Advisors first reported a position in Soleno Therapeutics in Q4 2023 and held it in 10 quarters.
Avoro Capital Advisors's Soleno Therapeutics position peaked at $180M in Q1 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Avoro Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.